SFRP5 and fatty liver disease: These results can be explained by the fact that SFRP5 is an anti-inflammatory molecule that seems to have a protective role in the first steps of hepatic steatosis, but then the inflammation seems to deregulated SFRP5 signaling, blocking its inhibition of the noncanonical WNT pathway, which promotes NAFLD progression.